InMed to Merge with Mentari as Mentari Secures $200M Pre-Closing Financing

InMed will combine with Mentari after Mentari raised $200 million in a pre-closing private placement to fund its migraine pipeline into 2029.

Key Highlights:

• $200M additional private placement of common stock and pre-funded warrants to close immediately before the merger.
• Financing expected to extend Mentari's cash runway into 2029 and through Phase 2a readouts for two PACAP-targeted programs, including MT-002.
• Additional securities will convert into InMed common shares or pre-funded warrants at the First Effective Time under merger terms.
• Pro forma ownership: pre-merger Mentari holders ~98.85%, pre-merger InMed shareholders ~1.15%; ~601.2M combined shares as-converted.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.